MCI/ PLMCIMG00012 /
| 23/08/2024 17:00:00 | Chg. -0.10 | Volume | Bid21:10:00 | Ask21:10:00 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 23.10PLN | -0.43% | 262 Turnover: 6,065.30 |
-Bid Size: - | -Ask Size: - | 1.21 bill.PLN | - | 7.36 |
GlobeNewswire
14/08
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
13/08
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
12/08
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
GlobeNewswire
12/08
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at...
GlobeNewswire
06/08
NFI subsidiary New Flyer named as partner of choice for more than $338 million in FTA Low- or No-Emi...
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
30/07
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire
28/07
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheime...
GlobeNewswire
28/07
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Stud...
GlobeNewswire
26/07
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire
25/07
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11/07
NFI subsidiary Alexander Dennis receives order from Stagecoach for 41 next-generation electric buses...
GlobeNewswire
10/07
Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharm...
GlobeNewswire
28/06
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire
25/06
NFI subsidiary Alexander Dennis receives largest single order of zero-emission buses ever, 244 next-...
GlobeNewswire
11/06
NFI subsidiary Alexander Dennis announces contract with Reading Buses for 53 buses including next-ge...
GlobeNewswire
10/06
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
10/06
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
